به جمع مشترکان مگیران بپیوندید!

تنها با پرداخت 70 هزارتومان حق اشتراک سالانه به متن مقالات دسترسی داشته باشید و 100 مقاله را بدون هزینه دیگری دریافت کنید.

برای پرداخت حق اشتراک اگر عضو هستید وارد شوید در غیر این صورت حساب کاربری جدید ایجاد کنید

عضویت
جستجوی مطالب مجلات
ردیف ۱۰-۱ از ۲۸۷۵ عنوان مطلب
|
  • مرجان جمالیان، وحید شایگان نژاد، سلیمان خیری، مرتضی سدهی، امید میر مسیب
    مقدمه
    درمان، نقش مهمی بر پیش گیری و کنترل حمله در بیماران Multiple sclerosis (MS) دارد. هدف از انجام این مطالعه، تعیین تاثیر نوع داروی مصرفی بر رخداد و تعداد حملات این بیماران است.
    روش ها
    در این مطالعه ی مقطعی، تعداد 1815 بیمار MS مراجعه کننده به بیمارستان آیت الله کاشانی اصفهان که اطلاعات آن ها در نرم افزار iMED ثبت شده بود و حداقل 34 ماه تحت پی گیری بودند، وارد مطالعه شدند. اثر نوع داروی مصرفی بر رخداد و تعداد حملات، با استفاده از مدل دو جمله ای منفی Hurdle با استفاده از نرم افزار R تعیین شد.
    یافته ها
    نوع داروی مصرفی اثر معنی داری بر رخداد حمله داشت؛ به گونه ای که در مقایسه با داروی بتا- اینترفرون 1a (Interferon beta-1a) (عضلانی)، داروهای بتا- اینترفرون 1a (زیر جلدی)، فینگولیمد (Fingolimod)، گلاتیرامر استات (Glatiramer acetate) و آزاتیوپرین به ویژه برای بیماران عود- فروکش کننده، اثر کمتری داشتند. بتا- اینترفرون 1b، اثر بیشتری و گلاتیرامر استات، اثر کمتری بر رخداد حمله به ترتیب در زنان و مردان داشت. در زنان، نوع داروهای مصرفی فینگولیمد، گلاتیرامر استات و آزاتیوپرین بر تعداد حملات اثر کمتری داشتند. سن بر رخداد و تعداد حملات در هر دو گروه مردان و زنان و هر دو سیر بالینی عود- فروکش کننده و پیش رونده، تاثیر معنی داری داشت.
    نتیجه گیری
    بیماران جوان تر، رخداد حمله ی بیشتری داشتند. داروی بتا- اینترفرون 1a (عضلانی) نسبت به سایر داروها در کاهش رخداد حمله عملکرد بهتری داشته است. در زنان، بیمارانی که داروی بتا- اینترفرون 1b را مصرف نموده اند، تعداد حملات کمتری نسبت به بیماران مصرف کننده ی داروی بتا- اینترفرون 1a (عضلانی) داشته اند. در بین مردان، بیماران با داروی مصرفی بتا- اینترفرون 1a (عضلانی) نسبت به گلاتیرامر استات رخداد حمله ی کمتری داشتند.
    کلید واژگان: Multiple sclerosis, درمان, داروهای تجویز شده, پیشرفت بیماری, عود
    Marjan Jamalian, Vahid Shaygannejad, Soleiman Kheiri, Morteza Sedehi, Omid Mirmosayyeb
    Background
    Treatment has a major effect on attacks in patients with multiple sclerosis (MS). This study aimed to determine the effect of the type of used drug on occurrence and number of attacks in patients with multiple sclerosis.
    Methods
    In this cross-sectional study, 1815 patients with multiple sclerosis referred to Ayatollah Kashani hospital in Isfahan, Iran, whose information was recorded in iMED software and followed at least for 34 months, were included. The effect of the type of drug on occurrence and number of attacks was determined using Negative Binomial Hurdle model by R software.
    Findings: The type of drug had a significant effect on the occurrence of attack; so that, compared to interferon beta-1a (muscle), interferon beta-1a (subcutaneous), fingolimod, glatiramer acetate and azathioprine were less effective, especially for relapsing-remitting types. Interferon beta-1b and glatiramer acetate had more and less effective on the occurrence of the attack in women and men, respectively. In women, fingolimod drugs, glatiramer acetate, and azathioprine had less effect on the number of attacks, respectively. The effect of age was significant on the occurrence and number of attacks in men and women, and both the recurrence and progressive clinical course.
    Conclusion
    Younger patients had more occurrences of attacks. Interferon beta-1a (muscle) has a better performance than other drugs in reducing occurrence of attacks. In women, patients taking interferon beta-1b had fewer attacks compared to patients taking interferon beta-1a (muscle). In men, patients taking interferon beta-1a (muscle) had fewer attacks than those taking glatiramer acetate.
    Keywords: Multiple sclerosis, Treatment, Prescription drugs, Disease progression, Relapse
  • Maryam Kay, Zohreh Hojati *, Fariba Dehghanian
    Multiple sclerosis (MS) is one of the most important autoimmune diseases recognized by demyelination and axonal lesion. It is the most common cause of disability in the young population. Various immunomodulatory and immunosuppressive therapies, including different formulations of interferon beta (IFNβ), glatiramer acetate (GA), mitoxantrone, and natalizumab are available for this disease. However, interferon has been the best prescribed. Although the precise mechanism of IFNβ is unclear, many studies indicate some potential mechanism including blocking T cells activation, controlling pro- and anti inflammatory cytokine secretion, preventing activated immune cell migration through BBB, and inducing repair activity of damaged nerve cells by differentiating neural stem cells into oligodendrocytes. These molecular mechanisms have significant roles in IFNβ therapy. More researches are required in order for us to comprehend the mechanism of action of IFNβ, and improve and develop drugs for more efficient MS treatment.
    Keywords: Interferon Beta, MS Treatment, Cytokine Shift, Blood Brain Barrier, MHC II
  • Hamed Cheraghmakani, Maryam Mobini, Mohammad Baghbanian
    Interferon (IFN) beta is the most widely prescribed disease-modifying drug for multiple sclerosis (MS). However, some adverse reactions are observed in course of IFN-beta therapy. This article presents two cases of female patients diagnosed with relapsing-remitting MS who developed inflammatory musculoskeletal manifestations, following IFN-beta 1a therapy. In the first patient recurrent arthritis developed a week after initiation of IFN-beta, which improved few weeks after a switch to glatiramer acetate. The second patient developed recurrent arthritis 1 month after IFN-beta 1a therapy who suffered painful arthritis despite discontinuation of the medication. Both patients were seropositive for anti- cyclic citrullinated peptide; the first patient was a positive rheumatoid factor (RF) and the second patient was both positive RF and anti-Ro. The role of IFN-beta in the setting of inflammatory musculoskeletal disease remains unclear. To minimize its side effects, review of these antibodies may be required in patients who are candidates for this therapy.
    Keywords: Arthritis, Multiple sclerosis, Interferon, beta
  • محمدرضا خجسته، سیدعلی شریعت رضوی، آیدا جوادزاده، علی گرجی، سجاد سحاب نگاه*
    مقدمه
    مالتیپل اسکلروز یک بیماری خود ایمنی سیستم عصبی مرکزی است که موجب دمیلینه شدن و آسیب به آکسون می شود. روش های درمانی متفاوتی از جمله: تجویز اینترفرون β، گلاتیرامراستات، ناتالیزوماب فینگولیمود و سایر عوامل تعدیل کننده سیستم ایمنی برای مالتیپل اسکلروز وجود دارد. در حال حاضر درمان پذیرفته شده برای مالتیپل اسکلروز در درجه اول کاهش التهاب سیستم عصبی مرکزی است. به طور قابل توجهی چالش حل نشده در زمینه مالتیپل اسکلروز پیشروی به سوی روش درمانی محافظت از نورون ها و میلین سازی مجدد برای درمان بیماران مبتلا به مالتیپل اسکلروز است. راهبردهای درمانی برای جلوگیری از آسیب بافتی و یا افزایش میلین سازی مجدد و بازسازی آکسونی به طور جدی مورد نیاز است.
    نتیجه گیری
    اخیرا کاربرد سلول درمانی برای درمان مالتیپل اسکلروز امید زیادی را جهت درمان بیماران مبتلا به مالتیپل اسکلروز ایجاد کرده است. چندین مطالعه نشان داده است که سلول درمانی تاثیرات ضد التهابی و تعدیل کننده ایمنی در بافت مغز دارد. در این مطالعه مروری ما ویژگی های انواع سلول های بنیادی و نقش آن ها در درمان مالتیپل اسکلروز را توضیح داده ایم.
    کلید واژگان: مالتیپل اسکلروز, سلول های بنیادی, میلین سازی مجدد, سیستم عصبی مرکزی
    Mohammad Reza Khojasteh, Ali Shariat Razavi Seyed, Aida Javadzadeh, Ali Gorji, Sajad Sahab Negah*
    Introduction
    Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) that can cause demyelination and axonal damage. There are different therapeutic approaches for MS, including administration of interferon-β, Glatiramer Acetate, Natalizumab, Fingolimod, and other immune-modulating agents. Currently approved MS treatments primarily decrease CNS inflammation. Noticeably, the unsolved challenge in the MS field is to advance neuroprotective and remyelinating approaches for the treatment of MS patients. Treatment strategies to prevent tissue damage and/or enhance remyelination and axonal regeneration are seriously needed.
    Conclusion
    Recently application of stem cell therapy for MS therapy has created a lot of hopes to treat MS patients. Several studies have been shown that stem cell therapy has immunomodulatory and anti-inflammatory effects in brain tissue. In this review, we have explained the properties of different types of stem cells and their role in the treatment of MS.
    Keywords: Multiple Sclerosis, Stem Cells, Remyelination, Central Nervous System
  • Seyed Mohammad Baghbanian, Mohammad Ali Sahraian
    Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence. Clinical or laboratory autoimmunity histories suggest the use of GA over INF-β as the treatment of choice
    Keywords: Interferon-Beta, Glatiramer Acetate, Autoimmune Disease, Multiple Sclerosis
  • SeyedMohammad Baghbanian*, Maryam Ghasemi, Somayeh Sheidaei, Zohreh Hajheydari
  • Khadijeh Gholinejad, Ali Rahimipour, Mohammad Ali Sahraian, Saeed Namaki, Faranak Kazerouni, Abdorreza Naser Moghadasi, Forough Rahimi, Nasrin Boroumandnia
    Myelin basic protein (MBP) is one of the most important constituents of the CNS myelin sheaths. It is supposed that an autoimmune response directed against MBP is crucial in the demyelination process in patients with multiple sclerosis. Studies have proved that free anti-MBP level in CSF of MS patients is declined when the patient entered into clinical remission. Some researchers evaluate the changes in serum or CSF level of this antibody during immunomodulatory therapy; the results are different and the relation between the changes in this antibody and response to treatment is poorly investigated. The objective of this study was to assess the relation between the changes in serum level of anti-MBP and clinical remission in patients during treatment with fingolimod. 37 MS patients that were non responder to interferon and glatiramer acetate and were candidates to receive fingolimod were nominated for this study. In this study, the serum level of anti-MBP was evaluated before and after 3 and 6 months of therapy and clinical remission was assessed by changes in Expanded Disability Status Scale (EDSS) scores. The result of this study showed that MS patients, after treatment with interferon, have lower serum anti-MBP level than healthy control group and this difference is statistically significant (p =0.03). The present study demonstrated that the serum anti-MBP level in MS patient during 6 months of treatment with fingolimod significantly decreased (p
    Keywords: Multiple sclerosis (MS), Anti, MBP, Fingolimod
  • MohammadMahdi Rabiei, Zahra Cheraghi, Mahtab Ramezani, Hossein Pakdaman

    Multiple sclerosis (MS) is a chronic inflammatory disease, causing neuronal demyelination and axonal damage in the central nervous system. Symptoms of MS vary widely because of different grades of sensory, motor, and cognitive dysfunctions. Although headache as the initial symptom of MS is rare, it is a common comorbidity that affects most patients. However, it is unclear that the headache manifestation in newly diagnosed people with MS should be considered as an MS attack or merely a comorbid condition. We report the case of a 31-year-old woman with newly diagnosed MS who presented with exacerbation of headache episodes without any abnormal neurological exam findings. The headaches did not respond to nonsteroidal anti-inflammatory drugs and triptans. After administration of methylprednisolone, the headaches were significantly improved, and during 3 months of follow-up receiving glatiramer acetate, no episode of headache has occurred. This case demonstrates the possible relationship between migraine and MS in newly diagnosed patients. New-onset headaches, a change in the pattern of previous episodes, and inadequate clinical drug response to headache treatment should all be taken seriously and warrant further investigation. Thereby, early diagnosis and proper treatment for patients with MS could improve their quality of life.

    Keywords: Migraine disorders, Headache, Multiple sclerosis, Treatment ou
  • Morteza Motallebnezhad, Shirin Taghizadeh, Tayebe Aghaie, Maryam Azimi, AliAkbar Salari, Mahmoud Bozorgmehr, Elahe Safari, Reza Falak, MirHadi Jazayeri

    Placental extract (PE) and exosomes from pregnant mice appear to have immunomodulatory and neuroprotective effects. In this study, we assessed the potential therapeutic effects of PE and exosomes obtained from pregnant mice in experimental autoimmune encephalomyelitis (EAE) mouse models. C57BL/6 mice, 8 to 12 weeks of age, were prepared and administered PE, exosomes, and glatiramer acetate (GA), as an FDA-approved treatment for multiple sclerosis (MS), after EAE induction. Thereafter, the therapeutic effects of treatment were evaluated by measuring the clinical courses of the mice as well as determining the number of regulatory T (Treg) cells using flow cytometry, cytokine levels, and microRNA-326 expression via real-time PCR. GA, PE, and exosomes reduced clinical severity, the extent of spinal cord demyelination, and the infiltration of inflammatory cells into the spinal cord. The frequency of CD4+CD25+FoxP3+ Treg cells increased after treatment of EAE mice with GA, PE, and exosomes. The mRNA expression of the inflammatory cytokines (interleukin-17  and interferon-gamma), as well as miR-326 expression, decreased significantly in the EAE mice after treatment with GA and exosomes. PE and exosomes from pregnant mice are involved in the modulation of Treg/Th17 balance and provide a therapeutic approach for MS. Further clinical studies will hopefully confirm the safety and efficacy of such treatments in MS patients.

    Keywords: Exosome, Experimental autoimmune encephalomyelitis, Glatiramer acetate, Multiple sclerosis, Placental extract
  • Fatima Molavi, Mohammad Barzegar-Jalali, Hamed Hamishehkar*
    Introduction

    Glatiramer acetate (GA) is a newly emerged therapeutic peptide to reduce the frequency of relapses in multiple sclerosis (MS). Despite its good performance in controlling MS, it is not widely used due to daily or biweekly subcutaneous injections due to rapid degradation and body clearance. Therefore, implant design with sustained release leads to prolonged biological effects by gradually increasing drug exposure and protecting GA from rapid local degradation.

    Methods

    Different emulsion methods, PLGA type, surfactant concentration, drug/polymer ratio, drying processes, stirring method, and other variables in preliminary studies modified the final formulation. The release kinetics were studied through mechanistic kinetic models such as zero-order, Weibull, Higuchi, etc. In this study, all challenges for easy scale-up, methodological detail, and a simple, feasible setup in mass production were discussed.

    Results

    The optimized formulation was obtained by 1:6 drug/PLGA, 0.5% w/w polyvinyl alcohol, and 0.75% w/w NaCl in the external aqueous phase, 1:10 continuous phase to dispersed phase ratio, and without any surfactant in the primary emulsion. The final freeze-dried particles presented a narrow distributed size of 1-10 µm with 7.29% ± 0.51 drug loading and zero-order release behavior with appropriate regression correlation (R2 98.7), complete release, and only 7.1% initial burst release.

    Conclusion

    Therefore, to achieve improvement in patient compliance through better and longer efficacy, designing the parenteral sustained release microspheres (MPSs) of this immune modulator is a promising approach that should be considered.

    Keywords: Peptide, protein, Drug delivery, Polymeric microparticles, Multiple sclerosis, Controlled release, Poly(D, L-lactic-co-glycolic acid)
نکته:
  • از آنجا که گزینه «جستجوی دقیق» غیرفعال است همه کلمات به تنهایی جستجو و سپس با الگوهای استاندارد، رتبه‌ای بر حسب کلمات مورد نظر شما به هر نتیجه اختصاص داده شده‌است‌.
  • نتایج بر اساس میزان ارتباط مرتب شده‌اند و انتظار می‌رود نتایج اولیه به موضوع مورد نظر شما بیشتر نزدیک باشند. تغییر ترتیب نمایش به تاریخ در جستجوی چندکلمه چندان کاربردی نیست!
  • جستجوی عادی ابزار ساده‌ای است تا با درج هر کلمه یا عبارت، مرتبط ترین مطلب به شما نمایش داده‌شود. اگر هر شرطی برای جستجوی خود در نظر دارید لازم است از جستجوی پیشرفته استفاده کنید. برای نمونه اگر به دنبال نوشته‌های نویسنده خاصی هستید، یا می‌خواهید کلمات فقط در عنوان مطلب جستجو شود یا دوره زمانی خاصی مدنظر شماست حتما از جستجوی پیشرفته استفاده کنید تا نتایج مطلوب را ببینید.
در صورت تمایل نتایج را فیلتر کنید:
متن مطلب
نوع نشریه
  • علمی
    2875
اعتبار نشریه
زبان مطلب
موضوعات گروه نشریات علمی
نتایج را در یکی از موضوعات زیر محدود کنید.
درخواست پشتیبانی - گزارش اشکال